Saturday, October 3, 2026

Aspen Group Stock Is 22% Down In The Last 5 Sessions

Aspen Group Stock Is 22% Down In The Last 5 Sessions

(VIANEWS) - Shares of Aspen Group (NASDAQ: ASPU) fell by a staggering 22.73% in 5 sessions from $0.22 at -22.73, to $0.17 at 15:00 EST on Friday, after three sequential sessions in a row of losses. NASDAQ is sliding 1.81% to $11,133.24, following the last session's downward trend.

Aspen Group's last close was $0.18, 90.66% under its 52-week high of $1.91.

About Aspen Group

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -28.28%.

Moving Average

Aspen Group's value is way under its 50-day moving average of $0.28 and way below its 200-day moving average of $0.62.

Yearly Top and Bottom Value

Aspen Group's stock is valued at $0.17 at 15:00 EST, below its 52-week low of $0.18.

Volume

Today's last reported volume for Aspen Group is 94599 which is 90.21% below its average volume of 355861.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aspen Group's stock is considered to be overbought (>=80).

More news about Aspen Group (ASPU).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com